Q-omics provides the consensus-scored PDE4DIPP2 profile across patient tissues and cancer cell-line models. PDE4DIPP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PDE4DIPP2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, PDE4DIPP2 RNA expression shows 19,968 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, KICH, and UVM as cancer lineages where PDE4DIPP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE4DIPP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE4DIPP2 survival associations across molecular data types. PDE4DIPP2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE4DIPP2 RNA expression–survival associations across cancer types. High PDE4DIPP2 expression shows unfavorable associations in LUSC, KIRC, CESC and LGG, but favorable associations in THCA and BRCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for PDE4DIPP2 RNA expression.
This table summarizes PDE4DIPP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PDE4DIPP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE4DIPP2 shows lower tumor expression in KICH, BRCA, LUSC and UCEC and higher tumor expression in LIHC and BLCA. The KICH box plot shows higher PDE4DIPP2 RNA expression in normal versus tumor tissue (log2 FC = −1.390, t-test p < 0.001).
This table shows molecular features associated with PDE4DIPP2 in patient tissues and cancer cell lines. In patient samples, PDE4DIPP2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE4DIPP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
